Level of Preparedness to Use Psilocybin Among Individuals Seeking Psychedelic Risk Reduction: A retrospective study of a pilot psychiatric consultation service
This retrospective study of 29 patients in an Oregon pilot psychiatric consultation service reveals that individuals seeking psilocybin risk reduction support typically have high baseline preparedness, a history of trauma and prior psychedelic use, and diverse motivations for seeking care, highlighting the emerging role of healthcare systems in providing evidence-based education and risk management as interest in psychedelics grows.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
In recent years, a quiet shift has occurred in how people in the United States view a specific type of mushroom. For decades, the active compound inside these fungi, known as psilocybin, was largely hidden from public view, restricted to the shadows of illegal markets or the tightly controlled walls of academic laboratories. Now, that landscape is changing. Oregon became the first state to create a legal pathway for people to receive psilocybin in a supervised setting, not as a prescription medication, but as a service. This new framework allows trained facilitators to guide individuals through the experience, aiming to help with mental health challenges like depression or trauma. However, this rapid opening of the door has created a new question for doctors and public health officials: as more people seek out these experiences, are they truly ready for what they might encounter? The medical community is still learning how to talk about the risks and benefits of these substances outside of formal research trials, especially for those who are not part of a clinical study.
To answer this question, a team of researchers at Oregon Health & Science University looked back at the early days of a new clinic designed specifically to help people prepare for this journey. This clinic, called PEACE, does not administer the drug itself. Instead, it acts as a consultation service where patients meet with doctors to discuss their medical history, their mental health, and their reasons for wanting to use psilocybin. The goal is to assess whether a person is at risk for a difficult or dangerous experience and to provide education on how to stay safe. The researchers wanted to understand who was walking through the doors of this clinic, what they hoped to achieve, and how prepared they felt before they even received any advice from a doctor.
The study focused on twenty-nine adults who visited the clinic between late 2023 and late 2025. These were not random people from the street; they were individuals who had taken the step to seek professional medical guidance before considering psilocybin. The group was diverse in age, with an average age of about forty-seven, but they shared some common traits. Most were white, most had private health insurance, and most held at least a bachelor's degree. Despite their different backgrounds, nearly all of them had a strong reason for coming in: three out of four were seeking help for a psychiatric concern, such as depression or anxiety, rather than a physical medical issue. A significant number, about eighty-six percent, reported having experienced some form of trauma in their lives, and many had already tried psilocybin or other hallucinogenic substances before.
Before their second visit, which focused on education and safety, the patients filled out a questionnaire designed to measure their level of preparedness. This tool asked them to rate how ready they felt to handle the experience, covering things like their understanding of the effects, their emotional stability, and their support system. The researchers found that, on average, these patients felt quite ready. Their scores were high, suggesting they had a solid foundation of knowledge and emotional readiness before the doctors even began their counseling. This was a surprising finding because the researchers had initially wondered if people with less money, those seeking treatment for severe mental illness, or those with a history of difficult drug experiences would feel less prepared. The data did not support that idea. Whether a patient had public or private insurance, whether they had used psychedelics before, or whether they had a history of trauma, their scores on the preparedness scale were remarkably similar.
The study also looked at whether the patients' medical or psychiatric risks were linked to how prepared they felt. The doctors had rated each patient's risk level, considering factors like heart health, past substance use, and mental health stability. The results showed no connection between these risk ratings and the patients' preparedness scores. A person with a higher medical risk was not necessarily less prepared, nor was someone with a lower risk score more ready. The only hint of a difference appeared in the numbers for those who had used psilocybin before; they tended to score slightly higher on preparedness than those who had never used it, but the difference was small and not statistically strong enough to be considered a definitive rule.
What emerges from this small group is a picture of a specific type of person navigating this new legal landscape. These are individuals who are often well-educated and financially stable, yet they carry significant emotional burdens, particularly related to past trauma. They are turning to medical professionals not because they are confused about the drug, but because they want to ensure they are safe and supported. The clinic they visited serves as a bridge, offering a space to discuss risks and expectations without the pressure of a formal research trial. The researchers suggest that this model of care—focusing on risk reduction and education rather than just treatment outcomes—could be a vital part of the future as more people seek these experiences. While the study is preliminary and involves a small number of people, it provides one of the first clear looks at who is seeking this kind of help and how they feel about it. It suggests that for many, the desire to use psilocybin is driven by a search for healing, and that having a medical professional to talk to before taking the step is a meaningful part of that process.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.